Opioid Toxicity in Advanced Cancer With Renal Impairment
A 64-year-old man (weight 70 kg) with metastatic pancreatic cancer and chronic kidney disease (eGFR 42 mL/min/1.73 m²) is followed by your palliative home-care team. His pain regimen is hydromorphone controlled-release 6 mg every 12 hours plus hydromorphone immediate-release 2 mg every 4 hours as needed. In the past 24 hours he has taken eight breakthrough doses. His wife reports increasing drowsiness, intermittent muscle jerks, and that he is difficult to rouse. Pain is now 4/10 at rest. Respiratory rate is 10/min, oxygen saturation is 94% on room air, and pupils are pinpoint. He continues senna, dexamethasone, and metoclopramide. The family asks whether the hydromorphone dose should be increased because he still has pain. You have no access to a palliative care physician for the next 12 hours. He has no history of substance use disorder.
1. Calculate his current total daily hydromorphone dose and oral morphine equivalent, and interpret the breakthrough use.
Read the worked answer
Total daily hydromorphone = CR 6 mg × 2 = 12 mg plus IR 2 mg × 8 = 16 mg, for 28 mg/day. Using an oral hydromorphone:oral morphine ratio of 1:5, this is approximately 140 mg oral morphine equivalent per day. The breakthrough dose is only 2 mg (about 7% of the total daily hydromorphone), which is below the usual 10–20% range; however, eight doses in 24 hours means 16 mg, or 57% of the scheduled dose, is being used as breakthrough. That pattern suggests poorly controlled baseline pain and/or tolerance, but the current drowsiness, myoclonus, and pinpoint pupils indicate toxicity, not a need to increase the opioid.
2. What is the likely cause of his current presentation, and what immediate actions are required?
Read the worked answer
The presentation is consistent with opioid toxicity, likely worsened by accumulation of hydromorphone metabolites in chronic kidney disease. Myoclonus, sedation, and respiratory rate 10 are red flags. Do not increase the dose. Hold all PRN hydromorphone now. Assess airway, breathing, and circulation; give naloxone only for respiratory rate below 8/min or unresponsiveness, titrated carefully because he is opioid-tolerant and abrupt reversal can precipitate severe pain and withdrawal. Contact the palliative care physician or on-call service urgently; if unavailable, arrange urgent clinical assessment. Monitor respiratory rate, sedation score, oxygen saturation, and pain every 30–60 minutes until stable. Reassess hydration, constipation, and other sedating medicines such as dexamethasone and metoclopramide.
3. Outline a safe adjustment and monitoring plan for the next 24 hours, including caregiver instructions.
Read the worked answer
After the patient is stable, reduce the total daily opioid dose by at least 25–30% and reassess. Because 6 mg CR capsules cannot be split, one practical option is hydromorphone CR 4 mg every 12 hours plus IR 1 mg every 4 hours as needed, with a maximum of four PRN doses per day; this provides about 12 mg/day and is a substantial reduction, so monitor for withdrawal and pain. Alternatively, consult palliative care about rotation to fentanyl, which is less dependent on renal function. Do not use a fentanyl patch for rapid titration. Continue senna and consider adding polyethylene glycol; avoid other sedatives. Teach the family not to give extra doses for pain while he is drowsy, to call if respiratory rate is below 10/min or he is hard to rouse, and to keep a written pain/sedation diary. Review in 12–24 hours.